Emerging Therapies for Triple-Negative Breast Cancer
- Tue, 2/15/11 - 2:55pm
- 0 Comments
- 828 reads
Anaheim—Although there are a few targeted therapies available to treat patients with triple-negative breast cancer (TNBC), they are not effective. However, researchers are working on new therapies that can be used alone or in combination with chemotherapy. Several experts provided an overview of TNBC and discussed past, current, and future trends associated with the disease during a symposium at the ASHP meeting titled Understanding Triple-Negative Breast Cancer and Emerging Targeted Therapies.
Atorvastatin Is More Cost-Effective than Rosuvastatin or Simvastatin/Ezetimibe
- Tue, 2/15/11 - 2:45pm
- 0 Comments
- 545 reads
Anaheim—An analysis of 3-year patient drug costs for branded statin therapies found that patients taking atorvastatin were less costly for managed care health plans to cover than patients taking rosuvastatin or a combination of simvastatin and ezetimibe. The 3-year net present cost for patients taking atorvastatin under a tier 3 nonpreferred formulary status was $774 compared with $1455 for rosuvastatin and $1159 for simvastatin and ezetimibe.
Optimizing Ultrafiltration Heparin Protocols
- Tue, 2/15/11 - 2:40pm
- 0 Comments
- 402 reads
Anaheim—A study found that heparin protocols involving higher target partial thromboplastin time (PTT) ranges, shorter recheck intervals, and higher PTT hold criteria may be effective in improving the safety and efficacy of ultrafiltration and decreasing hospital costs. The results were presented at the ASHP meeting during a poster presentation titled Adjustment of a Standardized Pharmacy Heparin Dosing Protocol for Use in Acute Heart Failure Patients Receiving Ultrafiltration.
Overview of Botulinum Toxin Products
- Tue, 2/15/11 - 2:34pm
- 0 Comments
- 700 reads
Anaheim—In the past 2 decades, the US Food and Drug Administration (FDA) has approved 4 products containing botulinum toxin; it has also required a risk evaluation and mitigation strategy (REMS) for each product: onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and rimabotulinumtoxinB. The FDA warns about the risk of spreading the potent toxin and provides guidelines and advice on how to best care for patients using the products.
Length of Hospital Stay in Patients Taking Ceftaroline Fosamil and Ceftriaxone
- Tue, 2/15/11 - 2:19pm
- 0 Comments
- 638 reads
Anaheim—A pooled analysis of 2 phase 3, double-blind, multinational, randomized controlled studies involving patients with community-acquired pneumonia (CAP) found that those taking ceftaroline fosamil spent less time in hospitals compared with those taking ceftriaxone. However, the results, presented during a poster session at the ASHP meeting, were not statistically significant.
Antiplatelet Therapy in Patients with Acute Coronary Syndrome
- Tue, 2/15/11 - 2:12pm
- 0 Comments
- 995 reads
Anaheim—To decrease the risk of patients with acute coronary syndrome (ACS) experiencing future coronary episodes, researchers are looking at the effectiveness of dual antiplatelet therapy. There are also emerging strategies such as triple antiplatelet therapy and additional antiplatelet agents in the pipeline that may help ACS patients.
At the ASHP meeting, speakers discussed recent clinical trials and oral antiplatelet therapies during a symposium titled Optimizing Oral Antiplatelet Therapy in Acute Coronary Syndrome.
Medical Homes May Be an Option to Reduce Costs and Improve Care
- Thu, 3/18/10 - 2:45pm
- 0 Comments
- 1163 reads
Las Vegas—Utilizing patient-centered medical homes and increasing the use of health information technology may help the healthcare industry battle growing healthcare costs while providing high-quality care. The benefits of medical homes and the role pharmacists can play in the treatment system were recently discussed in a session at the ASHP meeting.
According to David W. Bates, MD, the current medical system is broken and has “untenably” high costs and high levels of harm. Dr. Bates, who is the chief of the division of general
Get your Trends Smart Phone Mobile App Now!
